This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: Suzhou Galaxy Biopharma, Co., Ltd.. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Zhiyang Ling: Innovator in Monoclonal Antibody Development
Introduction
Zhiyang Ling is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on combating viral infections, showcasing his dedication to advancing medical science.
Latest Patents
Zhiyang Ling holds a patent for a human monoclonal antibody known as 8D6, which targets hepatitis C virus (HCV) infection. This innovative antibody binds to the E2 subunit of the HCV capsid protein, effectively preventing the virus from infecting susceptible host cells. The patent outlines methods for producing various forms of genetically engineered antibodies, which can be utilized in both prokaryotic and eukaryotic expression systems as therapeutics for HCV infection. He has 1 patent to his name.
Career Highlights
Zhiyang Ling is currently employed at Suzhou Galaxy Biopharma Co., Ltd., where he continues to work on groundbreaking research in the field of monoclonal antibodies. His expertise and innovative approach have positioned him as a key figure in the biotechnology sector.
Collaborations
Zhiyang has collaborated with notable colleagues, including Honglin Zhou and Jie Liu. Their combined efforts contribute to the advancement of therapeutic solutions in the fight against viral infections.
Conclusion
Zhiyang Ling's work in developing monoclonal antibodies represents a significant advancement in the treatment of hepatitis C virus infections. His innovative research and dedication to biotechnology continue to inspire progress in the medical field.